ID   UBR4_HUMAN              Reviewed;        5183 AA.
AC   Q5T4S7; A8MPT2; A8MQ33; A8MQB1; O60646; O75050; Q4QRK5; Q5T4S8; Q5T4S9;
AC   Q5TBN8; Q5TBP2; Q6DKH8; Q6P4A4; Q7L8P7; Q8IXJ4; Q8TDN5; Q8WV67; Q9HA46;
AC   Q9P2N9; Q9UG82;
DT   15-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 1.
DT   26-FEB-2020, entry version 156.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR4;
DE            EC=2.3.2.27;
DE   AltName: Full=600 kDa retinoblastoma protein-associated factor;
DE   AltName: Full=N-recognin-4;
DE   AltName: Full=RING-type E3 ubiquitin transferase UBR4;
DE   AltName: Full=Retinoblastoma-associated factor of 600 kDa;
DE            Short=RBAF600;
DE            Short=p600;
DE   AltName: Full=Zinc finger UBR1-type protein 1;
GN   Name=UBR4; Synonyms=KIAA0462, KIAA1307, RBAF600, ZUBR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH RB1 AND CALM,
RP   IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=16214886; DOI=10.1073/pnas.0507458102;
RA   Nakatani Y., Konishi H., Vassilev A., Kurooka H., Ishiguro K., Sawada J.,
RA   Ikura T., Korsmeyer S.J., Qin J., Herlitz A.M.;
RT   "p600, a unique protein required for membrane morphogenesis and cell
RT   survival.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15093-15098(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   PROTEIN SEQUENCE OF 166-185; 435-443; 850-857; 921-931; 1065-1079;
RP   1131-1141; 1175-1192; 1195-1208; 1286-1293; 1337-1349; 1434-1440;
RP   1464-1470; 1478-1489; 1731-1757; 1838-1850; 1875-1886; 1909-1918;
RP   1921-1931; 2048-2058; 2131-2138; 2211-2218; 2354-2381; 2527-2536;
RP   2564-2572; 2713-2721; 2981-2989; 3046-3065; 3229-3238; 3243-3252;
RP   3589-3606; 3618-3628; 3735-3745; 3809-3816; 3827-3836; 3845-3857;
RP   3889-3915; 4131-4142; 4204-4215; 4320-4334; 4414-4426; 4608-4637;
RP   4686-4696; 4717-4724; 4803-4814; 4852-4860; 5013-5022 AND 5062-5069,
RP   PHOSPHORYLATION AT SER-2719, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 779-5183 (ISOFORM 5).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2908-5183 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455484; DOI=10.1093/dnares/4.5.345;
RA   Seki N., Ohira M., Nagase T., Ishikawa K., Miyajima N., Nakajima D.,
RA   Nomura N., Ohara O.;
RT   "Characterization of cDNA clones in size-fractionated cDNA libraries from
RT   human brain.";
RL   DNA Res. 4:345-349(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4385-5183 (ISOFORMS 1 AND 2), AND
RP   VARIANT LEU-4867.
RC   TISSUE=Kidney, Liver, Lung, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4583-5183 (ISOFORM 1), AND VARIANTS LEU-4867
RP   AND ARG-4924.
RX   PubMed=16247014; DOI=10.1073/pnas.0500090102;
RA   Lennerz V., Fatho M., Gentilini C., Frye R.A., Lifke A., Ferel D.,
RA   Woelfel C., Huber C., Woelfel T.;
RT   "The response of autologous T cells to a human melanoma is dominated by
RT   mutated neoantigens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16013-16018(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4686-5183 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4709-5183 (ISOFORM 1), AND
RP   VARIANT LEU-4867.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   INTERACTION WITH HPV-16 E7; HPV-6B E7 AND HPV-11 E7 (MICROBIAL INFECTION),
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=16061792; DOI=10.1073/pnas.0505337102;
RA   Huh K.-W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., Muenger K.;
RT   "Association of the human papillomavirus type 16 E7 oncoprotein with the
RT   600-kDa retinoblastoma protein-associated factor, p600.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11492-11497(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181 AND THR-2715,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1084, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181 AND SER-1763,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2719, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-178; SER-181; THR-905;
RP   SER-1747; SER-1878; SER-1904; THR-2715 AND SER-2719, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and
RT   tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1647; SER-1652; THR-2944 AND
RP   SER-2952, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-1394.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which is a component of the N-end
CC       rule pathway. Recognizes and binds to proteins bearing specific N-
CC       terminal residues that are destabilizing according to the N-end rule,
CC       leading to their ubiquitination and subsequent degradation. Together
CC       with clathrin, forms meshwork structures involved in membrane
CC       morphogenesis and cytoskeletal organization. Regulates integrin-
CC       mediated signaling. May play a role in activation of FAK in response to
CC       cell-matrix interactions. Mediates ubiquitination of ACLY, leading to
CC       its subsequent degradation. {ECO:0000269|PubMed:16214886,
CC       ECO:0000269|PubMed:23932781}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with RB1 and calmodulin.
CC       {ECO:0000269|PubMed:16214886}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with protein E7 from papilloma
CC       virus HPV-16, HPV-6B and HPV-11. {ECO:0000269|PubMed:16061792}.
CC   -!- INTERACTION:
CC       P03129:E7 (xeno); NbExp=5; IntAct=EBI-1995940, EBI-866453;
CC       P04020:E7 (xeno); NbExp=2; IntAct=EBI-1995940, EBI-7005254;
CC       P06464:E7 (xeno); NbExp=2; IntAct=EBI-1995940, EBI-6944797;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Cytoplasm. Cytoplasm, cytoskeleton. Nucleus.
CC       Note=Concentrates at the leading edge of membrane structures involved
CC       in actin motility.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=Q5T4S7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5T4S7-2; Sequence=VSP_025209;
CC       Name=3;
CC         IsoId=Q5T4S7-3; Sequence=VSP_025203, VSP_025206;
CC       Name=4;
CC         IsoId=Q5T4S7-4; Sequence=VSP_025205, VSP_025206;
CC       Name=5;
CC         IsoId=Q5T4S7-5; Sequence=VSP_025201, VSP_025202, VSP_025204;
CC       Name=6;
CC         IsoId=Q5T4S7-6; Sequence=VSP_025200, VSP_025207, VSP_025208;
CC   -!- SIMILARITY: Belongs to the UBR4 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD43719.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF348492; AAL83880.1; -; mRNA.
DR   EMBL; AK022322; BAB14011.1; -; mRNA.
DR   EMBL; AL137127; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL357564; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB037728; BAA92545.1; -; mRNA.
DR   EMBL; AB007931; BAA32307.1; -; mRNA.
DR   EMBL; BC018694; AAH18694.2; -; mRNA.
DR   EMBL; BC063573; AAH63573.1; -; mRNA.
DR   EMBL; BC073905; AAH73905.1; -; mRNA.
DR   EMBL; BC096758; AAH96758.1; -; mRNA.
DR   EMBL; AJ505016; CAD43719.1; ALT_INIT; mRNA.
DR   EMBL; AL049972; CAB43227.1; -; mRNA.
DR   EMBL; AF055010; AAC09360.1; -; mRNA.
DR   CCDS; CCDS189.1; -. [Q5T4S7-1]
DR   PIR; T00076; T00076.
DR   RefSeq; NP_065816.2; NM_020765.2. [Q5T4S7-1]
DR   BioGrid; 116934; 148.
DR   CORUM; Q5T4S7; -.
DR   IntAct; Q5T4S7; 92.
DR   MINT; Q5T4S7; -.
DR   STRING; 9606.ENSP00000364403; -.
DR   DrugBank; DB05483; PCL-016.
DR   DrugBank; DB04959; Verpasep caltespen.
DR   CarbonylDB; Q5T4S7; -.
DR   iPTMnet; Q5T4S7; -.
DR   PhosphoSitePlus; Q5T4S7; -.
DR   SwissPalm; Q5T4S7; -.
DR   BioMuta; UBR4; -.
DR   DMDM; 74744979; -.
DR   EPD; Q5T4S7; -.
DR   jPOST; Q5T4S7; -.
DR   MassIVE; Q5T4S7; -.
DR   MaxQB; Q5T4S7; -.
DR   PaxDb; Q5T4S7; -.
DR   PeptideAtlas; Q5T4S7; -.
DR   PRIDE; Q5T4S7; -.
DR   ProteomicsDB; 64480; -. [Q5T4S7-1]
DR   ProteomicsDB; 64481; -. [Q5T4S7-2]
DR   ProteomicsDB; 64482; -. [Q5T4S7-3]
DR   ProteomicsDB; 64483; -. [Q5T4S7-4]
DR   ProteomicsDB; 64484; -. [Q5T4S7-5]
DR   ProteomicsDB; 64485; -. [Q5T4S7-6]
DR   Ensembl; ENST00000375218; ENSP00000364366; ENSG00000127481. [Q5T4S7-6]
DR   Ensembl; ENST00000375254; ENSP00000364403; ENSG00000127481. [Q5T4S7-1]
DR   GeneID; 23352; -.
DR   KEGG; hsa:23352; -.
DR   UCSC; uc001bbi.4; human. [Q5T4S7-1]
DR   CTD; 23352; -.
DR   DisGeNET; 23352; -.
DR   GeneCards; UBR4; -.
DR   HGNC; HGNC:30313; UBR4.
DR   HPA; HPA013394; -.
DR   HPA; HPA021046; -.
DR   MIM; 609890; gene.
DR   neXtProt; NX_Q5T4S7; -.
DR   OpenTargets; ENSG00000127481; -.
DR   PharmGKB; PA162407958; -.
DR   eggNOG; KOG1776; Eukaryota.
DR   eggNOG; ENOG410XPP8; LUCA.
DR   GeneTree; ENSGT00600000084471; -.
DR   HOGENOM; CLU_000069_0_0_1; -.
DR   InParanoid; Q5T4S7; -.
DR   KO; K10691; -.
DR   OMA; DEPHEYL; -.
DR   OrthoDB; 717at2759; -.
DR   PhylomeDB; Q5T4S7; -.
DR   TreeFam; TF314406; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBR4; human.
DR   GeneWiki; UBR4; -.
DR   GenomeRNAi; 23352; -.
DR   Pharos; Q5T4S7; Tbio.
DR   PRO; PR:Q5T4S7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q5T4S7; protein.
DR   Bgee; ENSG00000127481; Expressed in right testis and 130 other tissues.
DR   ExpressionAtlas; Q5T4S7; baseline and differential.
DR   Genevisible; Q5T4S7; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR025704; E3_Ub_ligase_UBR4.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   InterPro; IPR003126; Znf_UBR.
DR   Pfam; PF13764; E3_UbLigase_R4; 1.
DR   Pfam; PF02207; zf-UBR; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   SUPFAM; SSF48371; SSF48371; 2.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Calmodulin-binding; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Host-virus interaction; Membrane;
KW   Metal-binding; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase; Transmembrane; Transmembrane helix; Ubl conjugation pathway;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..5183
FT                   /note="E3 ubiquitin-protein ligase UBR4"
FT                   /id="PRO_0000286861"
FT   TRANSMEM        850..870
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        993..1013
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   ZN_FING         1656..1729
FT                   /note="UBR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00508"
FT   COMPBIAS        9..15
FT                   /note="Poly-Ala"
FT   COMPBIAS        608..631
FT                   /note="Pro-rich"
FT   COMPBIAS        2728..2738
FT                   /note="Poly-Asp"
FT   COMPBIAS        3339..3370
FT                   /note="Ser-rich"
FT   MOD_RES         178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         181
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         212
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AN08"
FT   MOD_RES         370
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AN08"
FT   MOD_RES         905
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1084
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         1402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q2TL32"
FT   MOD_RES         1647
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1652
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         1747
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1754
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q2TL32"
FT   MOD_RES         1763
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         1878
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         1904
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2715
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         2719
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000269|Ref.4"
FT   MOD_RES         2722
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AN08"
FT   MOD_RES         2724
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AN08"
FT   MOD_RES         2944
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         2952
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   VAR_SEQ         1..3585
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_025200"
FT   VAR_SEQ         2100
FT                   /note="K -> KQ (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10718198"
FT                   /id="VSP_025201"
FT   VAR_SEQ         2405..2486
FT                   /note="IGASVDPAGVTMIDAVKIYGKTKEQFGWPDEPPEEFPSASVSNICPSNLNQS
FT                   NGTGDSDSAAPTTTSGTVLERLVVSSLEAL -> SESPTPGADSVLIVTAKLGATGLWL
FT                   SNILGSLHSADFSVLSSGNFELHLMY (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10718198"
FT                   /id="VSP_025202"
FT   VAR_SEQ         2476
FT                   /note="E -> ESSETESLTKLD (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_025203"
FT   VAR_SEQ         2487..5183
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10718198"
FT                   /id="VSP_025204"
FT   VAR_SEQ         2601
FT                   /note="T -> TDCFFPRCACWSLGIVGILIGAPLETPSP (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_025205"
FT   VAR_SEQ         2830..2864
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_025206"
FT   VAR_SEQ         3777..3797
FT                   /note="DDSGTAGGISSTSASVNRYIL -> VVPRCKGHLDKGLGLDQKTAS (in
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_025207"
FT   VAR_SEQ         3798..5183
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_025208"
FT   VAR_SEQ         5108
FT                   /note="K -> KKQTTPTVGGIDTGSLEPCVCE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_025209"
FT   VARIANT         1107
FT                   /note="T -> A (in dbSNP:rs16862578)"
FT                   /id="VAR_032193"
FT   VARIANT         1394
FT                   /note="R -> H (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs756549939)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035540"
FT   VARIANT         4867
FT                   /note="M -> L (in dbSNP:rs12584)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16247014, ECO:0000269|Ref.10"
FT                   /id="VAR_032194"
FT   VARIANT         4924
FT                   /note="G -> R (in a melanoma patient)"
FT                   /evidence="ECO:0000269|PubMed:16247014"
FT                   /id="VAR_032195"
FT   VARIANT         5084
FT                   /note="V -> M (in dbSNP:rs2274010)"
FT                   /id="VAR_032196"
FT   CONFLICT        2016
FT                   /note="A -> S (in Ref. 1; AAL83880)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2410
FT                   /note="D -> E (in Ref. 1; AAL83880)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3957
FT                   /note="G -> S (in Ref. 1; AAL83880)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4589
FT                   /note="G -> V (in Ref. 7; AAH18694)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   5183 AA;  573841 MW;  5F6DD7B565E27609 CRC64;
     MATSGGEEAA AAAPAPGTPA TGADTTPGWE VAVRPLLSAS YSAFEMKELP QLVASVIESE
     SEILHHEKQY EPFYSSFVAL STHYITTVCS LIPRNQLQSV AAACKVLIEF SLLRLENPDE
     ACAVSQKHLI LLIKGLCTGC SRLDRTEIIT FTAMMKSAKL PQTVKTLSDV EDQKELASPV
     SPELRQKEVQ MNFLNQLTSV FNPRTVASQP ISTQTLVEGE NDEQSSTDQA SAIKTKNVFI
     AQNVASLQEL GGSEKLLRVC LNLPYFLRYI NRFQDAVLAN SFFIMPATVA DATAVRNGFH
     SLVIDVTMAL DTLSLPVLEP LNPSRLQDVT VLSLSCLYAG VSVATCMAIL HVGSAQQVRT
     GSTSSKEDDY ESDAATIVQK CLEIYDMIGQ AISSSRRAGG EHYQNFQLLG AWCLLNSLFL
     ILNLSPTALA DKGKEKDPLA ALRVRDILSR TKEGVGSPKL GPGKGHQGFG VLSVILANHA
     IKLLTSLFQD LQVEALHKGW ETDGPPAALS IMAQSTSIQR IQRLIDSVPL MNLLLTLLST
     SYRKACVLQR QRKGSMSSDA SASTDSNTYY EDDFSSTEED SSQDDDSEPI LGQWFEETIS
     PSKEKAAPPP PPPPPPLESS PRVKSPSKQA PGEKGNILAS RKDPELFLGL ASNILNFITS
     SMLNSRNNFI RNYLSVSLSE HHMATLASII KEVDKDGLKG SSDEEFAAAL YHFNHSLVTS
     DLQSPNLQNT LLQQLGVAPF SEGPWPLYIH PQSLSVLSRL LLIWQHKASA QGDPDVPECL
     KVWDRFLSTM KQNALQGVVP SETEDLNVEH LQMLLLIFHN FTETGRRAIL SLFVQIIQEL
     SVNMDAQMRF VPLILARLLL IFDYLLHQYS KAPVYLFEQV QHNLLSPPFG WASGSQDSNS
     RRATTPLYHG FKEVEENWSK HFSSDAVPHP RFYCVLSPEA SEDDLNRLDS VACDVLFSKL
     VKYDELYAAL TALLAAGSQL DTVRRKENKN VTALEACALQ YYFLILWRIL GILPPSKTYI
     NQLSMNSPEM SECDILHTLR WSSRLRISSY VNWIKDHLIK QGMKAEHASS LLELASTTKC
     SSVKYDVEIV EEYFARQISS FCSIDCTTIL QLHEIPSLQS IYTLDAAISK VQVSLDEHFS
     KMAAETDPHK SSEITKNLLP ATLQLIDTYA SFTRAYLLQN FNEEGTTEKP SKEKLQGFAA
     VLAIGSSRCK ANTLGPTLVQ NLPSSVQTVC ESWNNINTNE FPNIGSWRNA FANDTIPSES
     YISAVQAAHL GTLCSQSLPL AASLKHTLLS LVRLTGDLIV WSDEMNPPQV IRTLLPLLLE
     SSTESVAEIS SNSLERILGP AESDEFLARV YEKLITGCYN ILANHADPNS GLDESILEEC
     LQYLEKQLES SQARKAMEEF FSDSGELVQI MMATANENLS AKFCNRVLKF FTKLFQLTEK
     SPNPSLLHLC GSLAQLACVE PVRLQAWLTR MTTSPPKDSD QLDVIQENRQ LLQLLTTYIV
     RENSQVGEGV CAVLLGTLTP MATEMLANGD GTGFPELMVV MATLASAGQG AGHLQLHNAA
     VDWLSRCKKY LSQKNVVEKL NANVMHGKHV MILECTCHIM SYLADVTNAL SQSNGQGPSH
     LSVDGEERAI EVDSDWVEEL AVEEEDSQAE DSDEDSLCNK LCTFTITQKE FMNQHWYHCH
     TCKMVDGVGV CTVCAKVCHK DHEISYAKYG SFFCDCGAKE DGSCLALVKR TPSSGMSSTM
     KESAFQSEPR ISESLVRHAS TSSPADKAKV TISDGKVADE EKPKKSSLCR TVEGCREELQ
     NQANFSFAPL VLDMLNFLMD AIQTNFQQAS AVGSSSRAQQ ALSELHTVEK AVEMTDQLMV
     PTLGSQEGAF ENVRMNYSGD QGQTIRQLIS AHVLRRVAMC VLSSPHGRRQ HLAVSHEKGK
     ITVLQLSALL KQADSSKRKL TLTRLASAPV PFTVLSLTGN PCKEDYLAVC GLKDCHVLTF
     SSSGSVSDHL VLHPQLATGN FIIKAVWLPG SQTELAIVTA DFVKIYDLCV DALSPTFYFL
     LPSSKIRDVT FLFNEEGKNI IVIMSSAGYI YTQLMEEASS AQQGPFYVTN VLEINHEDLK
     DSNSQVAGGG VSVYYSHVLQ MLFFSYCQGK SFAATISRTT LEVLQLFPIN IKSSNGGSKT
     SPALCQWSEV MNHPGLVCCV QQTTGVPLVV MVKPDTFLIQ EIKTLPAKAK IQDMVAIRHT
     ACNEQQRTTM ILLCEDGSLR IYMANVENTS YWLQPSLQPS SVISIMKPVR KRKTATITTR
     TSSQVTFPID FFEHNQQLTD VEFGGNDLLQ VYNAQQIKHR LNSTGMYVAN TKPGGFTIEI
     SNNNSTMVMT GMRIQIGTQA IERAPSYIEI FGRTMQLNLS RSRWFDFPFT REEALQADKK
     LNLFIGASVD PAGVTMIDAV KIYGKTKEQF GWPDEPPEEF PSASVSNICP SNLNQSNGTG
     DSDSAAPTTT SGTVLERLVV SSLEALESCF AVGPIIEKER NKNAAQELAT LLLSLPAPAS
     VQQQSKSLLA SLHTSRSAYH SHKDQALLSK AVQCLNTSSK EGKDLDPEVF QRLVITARSI
     AIMRPNNLVH FTESKLPQME TEGMDEGKEP QKQLEGDCCS FITQLVNHFW KLHASKPKNA
     FLAPACLPGL THIEATVNAL VDIIHGYCTC ELDCINTASK IYMQMLLCPD PAVSFSCKQA
     LIRVLRPRNK RRHVTLPSSP RSNTPMGDKD DDDDDDADEK MQSSGIPNGG HIRQESQEQS
     EVDHGDFEMV SESMVLETAE NVNNGNPSPL EALLAGAEGF PPMLDIPPDA DDETMVELAI
     ALSLQQDQQG SSSSALGLQS LGLSGQAPSS SSLDAGTLSD TTASAPASDD EGSTAATDGS
     TLRTSPADHG GSVGSESGGS AVDSVAGEHS VSGRSSAYGD ATAEGHPAGP GSVSSSTGAI
     STTTGHQEGD GSEGEGEGET EGDVHTSNRL HMVRLMLLER LLQTLPQLRN VGGVRAIPYM
     QVILMLTTDL DGEDEKDKGA LDNLLSQLIA ELGMDKKDVS KKNERSALNE VHLVVMRLLS
     VFMSRTKSGS KSSICESSSL ISSATAAALL SSGAVDYCLH VLKSLLEYWK SQQNDEEPVA
     TSQLLKPHTT SSPPDMSPFF LRQYVKGHAA DVFEAYTQLL TEMVLRLPYQ IKKITDTNSR
     IPPPVFDHSW FYFLSEYLMI QQTPFVRRQV RKLLLFICGS KEKYRQLRDL HTLDSHVRGI
     KKLLEEQGIF LRASVVTASS GSALQYDTLI SLMEHLKACA EIAAQRTINW QKFCIKDDSV
     LYFLLQVSFL VDEGVSPVLL QLLSCALCGS KVLAALAASS GSSSASSSSA PVAASSGQAT
     TQSKSSTKKS KKEEKEKEKD GETSGSQEDQ LCTALVNQLN KFADKETLIQ FLRCFLLESN
     SSSVRWQAHC LTLHIYRNSS KSQQELLLDL MWSIWPELPA YGRKAAQFVD LLGYFSLKTP
     QTEKKLKEYS QKAVEILRTQ NHILTNHPNS NIYNTLSGLV EFDGYYLESD PCLVCNNPEV
     PFCYIKLSSI KVDTRYTTTQ QVVKLIGSHT ISKVTVKIGD LKRTKMVRTI NLYYNNRTVQ
     AIVELKNKPA RWHKAKKVQL TPGQTEVKID LPLPIVASNL MIEFADFYEN YQASTETLQC
     PRCSASVPAN PGVCGNCGEN VYQCHKCRSI NYDEKDPFLC NACGFCKYAR FDFMLYAKPC
     CAVDPIENEE DRKKAVSNIN TLLDKADRVY HQLMGHRPQL ENLLCKVNEA APEKPQDDSG
     TAGGISSTSA SVNRYILQLA QEYCGDCKNS FDELSKIIQK VFASRKELLE YDLQQREAAT
     KSSRTSVQPT FTASQYRALS VLGCGHTSST KCYGCASAVT EHCITLLRAL ATNPALRHIL
     VSQGLIRELF DYNLRRGAAA MREEVRQLMC LLTRDNPEAT QQMNDLIIGK VSTALKGHWA
     NPDLASSLQY EMLLLTDSIS KEDSCWELRL RCALSLFLMA VNIKTPVVVE NITLMCLRIL
     QKLIKPPAPT SKKNKDVPVE ALTTVKPYCN EIHAQAQLWL KRDPKASYDA WKKCLPIRGI
     DGNGKAPSKS ELRHLYLTEK YVWRWKQFLS RRGKRTSPLD LKLGHNNWLR QVLFTPATQA
     ARQAACTIVE ALATIPSRKQ QVLDLLTSYL DELSIAGECA AEYLALYQKL ITSAHWKVYL
     AARGVLPYVG NLITKEIARL LALEEATLST DLQQGYALKS LTGLLSSFVE VESIKRHFKS
     RLVGTVLNGY LCLRKLVVQR TKLIDETQDM LLEMLEDMTT GTESETKAFM AVCIETAKRY
     NLDDYRTPVF IFERLCSIIY PEENEVTEFF VTLEKDPQQE DFLQGRMPGN PYSSNEPGIG
     PLMRDIKNKI CQDCDLVALL EDDSGMELLV NNKIISLDLP VAEVYKKVWC TTNEGEPMRI
     VYRMRGLLGD ATEEFIESLD STTDEEEDEE EVYKMAGVMA QCGGLECMLN RLAGIRDFKQ
     GRHLLTVLLK LFSYCVKVKV NRQQLVKLEM NTLNVMLGTL NLALVAEQES KDSGGAAVAE
     QVLSIMEIIL DESNAEPLSE DKGNLLLTGD KDQLVMLLDQ INSTFVRSNP SVLQGLLRII
     PYLSFGEVEK MQILVERFKP YCNFDKYDED HSGDDKVFLD CFCKIAAGIK NNSNGHQLKD
     LILQKGITQN ALDYMKKHIP SAKNLDADIW KKFLSRPALP FILRLLRGLA IQHPGTQVLI
     GTDSIPNLHK LEQVSSDEGI GTLAENLLEA LREHPDVNKK IDAARRETRA EKKRMAMAMR
     QKALGTLGMT TNEKGQVVTK TALLKQMEEL IEEPGLTCCI CREGYKFQPT KVLGIYTFTK
     RVALEEMENK PRKQQGYSTV SHFNIVHYDC HLAAVRLARG REEWESAALQ NANTKCNGLL
     PVWGPHVPES AFATCLARHN TYLQECTGQR EPTYQLNIHD IKLLFLRFAM EQSFSADTGG
     GGRESNIHLI PYIIHTVLYV LNTTRATSRE EKNLQGFLEQ PKEKWVESAF EVDGPYYFTV
     LALHILPPEQ WRATRVEILR RLLVTSQARA VAPGGATRLT DKAVKDYSAY RSSLLFWALV
     DLIYNMFKKV PTSNTEGGWS CSLAEYIRHN DMPIYEAADK ALKTFQEEFM PVETFSEFLD
     VAGLLSEITD PESFLKDLLN SVP
//
